SMARCA4 and gastric cancer: By staining 18 different tumor microarrays (TMAs), we observed BRG1 loss greater than or equal to 10% of the tumor cells in 14 of the 18 TMAs that were analyzed (Figure 1 and Supplementary Table 2A-G), while we observed little to no negativity (i.e., no BRG1 loss) in one cancer type, stomach cancer (< 1%) (Supplementary Table 2A).